What You Should Know:
– Caris Life Sciences (Caris), a leader in AI-powered precision medicine, and COTA, Inc., a real-world data (RWD) and analytics expert, announced a strategic collaboration today.
– The strategic partnership aims to revolutionize cancer treatment development and patient care by leveraging a powerful combination of data: Caris’ extensive molecular data and COTA’s real-world patient information.
Real-World Data Fusion for Precision Medicine
This collaboration brings together unparalleled resources:
- Caris’ Molecular Expertise: Caris boasts a vast molecular database encompassing nearly 10 million tests, containing over 60 petabytes of data. This includes genomic, transcriptomic, proteomic, and imaging data, offering a comprehensive picture of each patient’s cancer.
- COTA’s Real-World Insights: COTA contributes real-world data from over 2 million cancer patients treated across diverse healthcare settings. This data captures the actual treatment journeys and outcomes of patients, providing invaluable insights into real-world effectiveness.
By combining these datasets, the collaboration aims to create a unique, large-scale, multi-modal data offering. This will empower researchers and pharmaceutical companies to:
- Develop More Effective Cancer Therapies: The comprehensive picture of patients’ molecular profiles and real-world treatment responses will guide the development of targeted and personalized cancer treatments.
- Accelerate Drug Discovery: The vast amount of data will allow for faster identification of promising drug candidates and optimization of clinical trials.
- Improve Patient Care: Ultimately, this collaboration aims to translate data insights into improved patient care by enabling the development of more effective and personalized cancer treatments.
“Caris’ partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development. This breadth of data allows the flexibility to build specific cohorts for understanding mechanisms of resistance, determinants of response and relevant biomarkers to improve success of their clinical trials,” said Brian Lamon, PhD, Chief Business Officer at Caris.
